Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
Key Points
Key Points
- This guideline focuses on patients with advanced, recurrent, or metastatic prostate cancer and noncastrate testosterone levels whose disease is not yet castration-resistant, including those with biochemical recurrence only.
- The future of noncastrate advanced, recurrent, or metastatic prostate cancer care is predicted to include highly personalized treatment plans based on advanced genetic testing, next generation imaging, and the availability of highly predictive biomarkers.
- This targeted update is driven by results from recent Phase III clinical trials (ARASENS, PEACE-1, ENZAMET, and ARCHES) and two recent meta-analyses.
Treatment
...reatmen...
Initial Treat...
...1.0(Updated) Docetaxel, abiraterone, enzalutam...
...DROGEN DEPRIVATION THERAPY (ADT) PLUS DOCETAX...
...n 1.1(Updated) For patients with metas...
...commendation 1.11(New) For patients with de novo m...
...ion 1.15(New) For patients with de novo...
...ndation 1.16(New) The recommended...
...1.2(Updated) For patients with low-volume me...
...on 1.3(Updated) For patients with metastat...
...PLUS ABIRATERONE...
...on 1.4For patients with high-risk de novo...
...ommendation 1.5For patients with low...
...1.6The recommended regimen for patient...
...S ENZALUTAMIDE...
...ation 1.7(Updated) ADT plus enzalutam...
...1.8(Updated) The recommended regimen...
...PLUS APALUTAMIDE...
...commendation 1.9ADT plus apalutamide should al...
...1.95(Updated) The recommended regim...
...nation Therapies...
...ion 2.1ADT plus abiraterone and prednisolone shou...
...ion 2.2In resource-constrained settings where dru...
Early Androgen Deprivat...
...ommendation 3.1Early (immediate) ADT may be of...
...tent Androgen Deprivation...
...dation 4.1Intermittent therapy may be offer...
...gure 1. Initial Management of Noncas...